

# UC Davis

## UC Davis Previously Published Works

### Title

Clinical implications of somatic allele expansion in female FMR1 premutation carriers

### Permalink

<https://escholarship.org/uc/item/3gv7k63b>

### Journal

Scientific Reports, 13(1)

### ISSN

2045-2322

### Authors

Aishworiya, Ramkumar

Hwang, Ye Hyun

Santos, Ellery

et al.

### Publication Date

2023

### DOI

10.1038/s41598-023-33528-x

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



OPEN

# Clinical implications of somatic allele expansion in female *FMR1* premutation carriers

Ramkumar Aishworiya<sup>1,2,3,8</sup>, Ye Hyun Hwang<sup>4,8</sup>, Ellery Santos<sup>1,5</sup>, Bruce Hayward<sup>6</sup>, Karen Usdin<sup>6</sup>, Blythe Durbin-Johnson<sup>7</sup>, Randi Hagerman<sup>1,5</sup> & Flora Tassone<sup>1,4</sup>✉

Carriers of a premutation allele (PM) in the *FMR1* gene are at risk of developing a number of Fragile X premutation associated disorders (FXPAC), including Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), Fragile X-associated Primary Ovarian Insufficiency (FXPOI), and Fragile X-associated neuropsychiatric disorders (FXAND). We have recently reported somatic CGG allele expansion in female PM; however, its clinical significance remains unclear. The aim of this study was to examine the potential clinical association between somatic *FMR1* allele instability and PM associated disorders. Participants comprised of 424 female PM carriers age 0.3–90 years. *FMR1* molecular measures and clinical information on the presence of medical conditions, were determined for all subjects for primary analysis. Two sub-groups of participants (age  $\geq 25$ , N = 377 and age  $\geq 50$ , N = 134) were used in the analysis related to presence of FXPOI and FXTAS, respectively. Among all participants (N = 424), the degree of instability (expansion) was significantly higher (median 2.5 vs 2.0,  $P = 0.026$ ) in participants with a diagnosis of attention deficit hyperactivity disorder (ADHD) compared to those without. *FMR1* mRNA expression was significantly higher in subjects with any psychiatric disorder diagnosis ( $P = 0.0017$ ); specifically, in those with ADHD ( $P = 0.009$ ), and with depression ( $P = 0.025$ ). Somatic *FMR1* expansion was associated with the presence of ADHD in female PM and *FMR1* mRNA levels were associated with the presence of mental health disorders. The findings of our research are innovative as they suggest a potential role of the CGG expansion in the clinical phenotype of PM and may potentially guide clinical prognosis and management.

## Abbreviations

PM	Premutation
ADHD	Attention deficit hyperactivity disorder
FXTAS	Fragile X-associated Tremor/Ataxia Syndrome
FXPOI	Fragile X-associated Primary Ovarian Insufficiency
FXAND	Fragile X-associated Neuropsychiatric Disorders
ASD	Autism spectrum disorder
CE	Capillary electrophoresis
RFU	Relative fluorescence units

The fragile X premutation carrier status has received growing recognition as a distinct clinical and molecular entity beyond Fragile X syndrome (FXS) over the past two decades. PM individuals have between 55 to 200 CGG repeats in the 5' region of the *FMR1* gene and typically pass on the mutation to their offspring, with a propensity

<sup>1</sup>Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, 2825 50Th Street, Sacramento, CA 95817, USA. <sup>2</sup>Khoo Teck Puat-National University Children's Medical Institute, National University Health System, 5 Lower Kent Ridge Road, Singapore 119074, Singapore. <sup>3</sup>Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Drive, Singapore 117597, Singapore. <sup>4</sup>Department of Biochemistry and Molecular Medicine, University of California Davis, School of Medicine, 4610 X St, Sacramento, CA 95817, USA. <sup>5</sup>Department of Pediatrics, University of California Davis, School of Medicine, 4610 X St, Sacramento, CA 95817, USA. <sup>6</sup>Laboratory of Cell and Molecular Biology, Digestive and Kidney Diseases, National Institute of Diabetes, 9000 Rockville Pike, Bethesda, MD 20892, USA. <sup>7</sup>Department of Public Health Sciences, University of California, Davis, School of Medicine, 4610 X St, Sacramento, CA 95817, USA. <sup>8</sup>These authors contributed equally: Ramkumar Aishworiya and Ye Hyun Hwang. ✉email: ftassone@ucdavis.edu

for expansion to the full mutation state (> 200 CGG repeats) in each subsequent generation<sup>1</sup>. While FXS is one of the most common single gene disorders causing intellectual disability, the premutation status is more common and occurs in approximately 1 in 400 males and 1 in 200 females<sup>2</sup>. We now know that the premutation status is associated with specific clinical conditions including Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), Fragile X-associated Primary Ovarian Insufficiency (FXPOI), and Fragile X-associated Neuropsychiatric Disorders (FXAND)<sup>3–5</sup>. Other research groups have referred to these neuropsychiatric and other conditions associated with the premutation as Fragile X-premutation associated conditions (FXPAC) due to concerns of stigma associated with the term ‘disorder’. Regardless, it is important to recognize the presence and burden of these conditions in PM carriers as many of them are associated with significant comorbidity.

Occurrence of these disorders varies across PM with gender differences as well. For instance, FXTAS is seen in 40–75% of male PM and 8–16% of females<sup>6,7</sup>. Common FXAND conditions include anxiety (occurring in 50–70% of carriers) and depression (40–65% of carriers) but increasingly, attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) have also been reported to be more common in PM, with reported prevalence rates of 30–45% and 8% respectively<sup>8–12</sup>. The molecular basis behind these disorders is attributed to the toxicity related to elevated levels of *FMRI* mRNA seen in PM<sup>13,14</sup>. This is proposed to interfere with various cellular functions through mitochondrial dysfunction, calcium dysregulation and cell/DNA damage repair functions<sup>13,15–17</sup>.

Instability of the *FMRI* premutation allele has recently been described for the first time by our group on a large sample of female PM<sup>18</sup>. Specifically, we characterized the presence of a series of unstable expanded alleles in ~94% of peripheral blood samples differing from the major premutation allele by one or more repeat units. The degree of expansion was directly proportional to the number of CGG repeats in the original allele with an indication that the extent of the expansion increased with age as well. Expansion was also inversely proportional to the number of AGG anchors which are considered to be ‘stabilizers’ that prevent CGG expansion across generations. However, the clinical implications of the presence and degree of this somatic expansion is, as yet, unclear. Indeed, given that this observation was based on peripheral blood sample, how this translates to brain tissue and its possible implications especially in the pathophysiology of neurologic premutation associated conditions like FXAND and FXTAS are important areas for further studies.

The aim of this study was to examine the potential clinical associations between somatic expansion in female PM and premutation associated conditions. We hypothesized that a higher degree of expansion will be associated with a greater occurrence of disorders; and hence planned for separate sub-group analysis by age-range of the cohort a priori.

## Methods

**Subjects.** Participants in this study included 424 female PM age 0.3–90 years whose premutation status (CGG repeat size 55–200) was confirmed by PCR/Southern blot testing. *FMRI* molecular measures and clinical information, were determined for all 424 subjects and used in the primary analysis. In addition, participants were divided in two additional sub-groups for the analysis related to the presence of FXPOI and FXTAS (age ≥ 25, N = 377, and age ≥ 50, N = 134 respectively).

Participants were enrolled either as part of a dedicated research visit or following cascade testing after consultation for a child or sibling with fragile X syndrome. The study and all research protocols were carried out in accordance with and was approved by the Institutional Review Board at the University of California, Davis. All participants gave written informed consent before participating in the study.

**Clinical information.** Clinical information on the presence and severity of FXTAS, presence of FXPOI, presence of FXAND disorders, neurological symptoms, chronic medical problems and auto-immune conditions and demographic variables including weight, height, history of smoking and education level were documented on a data sheet filled out in taking the medical history. Ascertainment of presence and stage (range 1–5) of FXTAS was made by an experienced physician (RJH) who has several years of experience with PM patients, following detailed medical examination and review of Magnetic Resonance Imaging images of patients. Presence of FXPOI was defined as occurrence of early menopause prior to 40 years of age.

Presence of FXAND disorders was determined based on DSM-5 criteria for respective FXAND conditions, following evaluation by a trained medical provider or psychologist. FXAND disorders examined, specifically included anxiety, depression, ASD and ADHD and standardized assessments such as the Autism Diagnostic Observation Schedule (ADOS)<sup>19</sup>, the Structured Clinical Interview for DSM-5 (SCID-5)<sup>20</sup>, and the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)<sup>21</sup>, for younger patients, were used. Information on results of the SCID-5 in terms of presence of at least 1 psychiatric disorder (e.g. specific phobias, social phobia, generalized anxiety disorder, major depressive disorder) was obtained. A cognitive assessment based on standardized testing was carried out. Given the wide age-range of participants, a variety of standardized cognitive assessments were used across study participants. These included the Wechsler Intelligence Scale for Children, Third or Fourth Edition (WISC-III or WISC-IV)<sup>22</sup>, the Stanford Binet Intelligence Scales, Fifth Edition (SB-5)<sup>23</sup>, and the Wechsler Adult Intelligence Scale, Third or Fourth Edition (WAIS-III or WAIS-IV)<sup>24</sup>, as per participant age.

Specific chronic medical conditions of interest comprised hyper or hypothyroidism, diabetes mellitus, migraine, osteoporosis, seizures and autonomic dysfunction such as urinary incontinence. Information on these conditions were collapsed into a single category titled chronic medical conditions with presence of at least 1 condition and number of conditions collected. Specific auto-immune conditions included systemic lupus erythematosus, rheumatoid arthritis, fibromyalgia, autoimmune thyroid conditions and multiple sclerosis. Similarly, presence of at least 1 auto-immune condition and number of such conditions was collected under the category of auto-immune conditions.

**Molecular data.** Molecular data, including CGG allele repeat size, AGG interruptions and expansion were obtained from DNA samples isolated from 3 mL of whole blood using the Gentra Puregene Blood Kit (Qiagen, Valencia, CA, USA). *FMRI* allele size was assessed through PCR and Southern blot analysis as previously described<sup>25,26</sup>. PCR used specific *FMRI* primers (AmplideX PCR/CE, Asuragen) and PCR products were visualized by capillary electrophoresis (CE). Southern blot analysis was used to determine the methylation status of the *FMRI* alleles (Activation ratio, AR and percent of methylation) as reported in Tassone et al.<sup>27</sup> The AR value indicates the percentage of cells carrying the normal allele on the active X-chromosome. The number of AGG interruptions were quantified with a triplet primed PCR protocol as reported in Yrigollen et al.<sup>28,29</sup>, which was then visualized with CE and analyzed with Peak Scanner Software 2.0. To quantify the degree of expansion in each participant, the original size allele (Peak 1) and the modal expanded allele (Peak 2) needed to be identified, in which identification of Peak 1 was facilitated by X-inactivation in females. The expanded peak with the highest relative fluorescence units (RFU) value was selected as Peak 2. Expansion was calculated using the formula (Peak 2–Peak 1), more details can be found in Hwang et al.<sup>18</sup>. Total RNA was isolated from 2.5 ml of peripheral blood collected in PAXgene (Qiagen, Valencia, CA, United States) and quantified using the Agilent 2100 Bioanalyzer system. To measure *FMRI* transcript expression levels, qRT-PCR used Assays-On-Demand (Applied Biosystems, Foster City, CA, USA) and custom TaqMan primers and probe assays as specified by Tassone et al.<sup>13</sup>.

**Statistical analysis.** All analysis was conducted using R version 4.0.5 (2021-03-31). Analysis was conducted on all participants (0.3–90 years old) as well as on those age  $\geq 25$  years (FXPOI group) and those  $\geq 50$  years (FXTAS group) as separate sub-groups. Specific measures analyzed in the FXPOI group was the age at menopause and the presence of FXPOI while that in the FXTAS group was the presence and the stage of FXTAS. Expansion was measured as described in our previous paper<sup>18</sup> but in essence, instability was represented by  $\Delta Rpts$ , which, in a repeat profile, represents the difference in the number of repeats between the modal expanded allele (Peak 2) and modal stable allele (Peak 1). Spearman test of correlation were used to examine CGG repeat length, *FMRI* mRNA expression, and expansion (measured as peak 2—peak 1) against IQ measures. CGG repeat length, *FMRI* mRNA expression, and expansion, were compared between subjects with and without a given clinical condition using Wilcoxon rank sum tests. *FMRI* was modelled by CGG, adjusting for activation ratio (AR), using a linear regression model with *FMRI* as the response and CGG and AR as covariates. Analyses of associations between expansion and clinical phenotype was not adjusted for CGG repeat number as none of the clinical conditions were significantly associated with the number of CGG repeats and CGG repeats furthermore did not differ meaningfully between subjects with and without a given condition.

**Ethics approval and consent to participate.** The study and all research protocols were carried out in accordance with the Institutional Review Board at the University of California, Davis. All participants gave written informed consent before participating in the study.


## Results

The final number of participants consisted of 424 female PM with an age range of 0.3 to 90 years. The mean number of CGG repeats was 92.1 (SD 23.0); premutation expansion, was present in all 424 participants and somatic instability, as illustrated in Fig. 1, was present in ~92% of them. Average full-scale IQ of participants was 119.8 (SD 19.0). Table 1 shows the descriptive molecular and clinical data of the three groups of participants. There was a large range of clinical conditions present within participants with the most common ones being anxiety (77.3% of those who had available data) and depression (63.6%). The majority of the participants (84.0%) had at least one FXAND condition. Among the 43 participants who had FXPOI within the  $\geq 25$  years old sub-group, 36 (85.7%) had anxiety, 30 (71.4%) had depression, 13 (30.2%) had autoimmune conditions.

Looking at the entire cohort, the degree of expansion was significantly higher in participants with a diagnosis of ADHD (median difference 2.5) compared to those without the diagnosis (median difference 2.0,  $P=0.026$ ) (Table 2). A sensitivity analyses of the association between instability and ADHD, adjusting for age, yielded the same conclusions as the unadjusted analysis. Expansion was not associated with any other clinical condition. *FMRI* mRNA expression was significantly higher in participants with at least 1 SCID-5 diagnosis (median difference 1.98 vs 0.87,  $P=0.0017$ ), in those with ADHD (2.30 vs 2.04,  $P=0.009$ ), in those with depression (2.19 vs 1.98,  $P=0.025$ ) and in those with at least 1 FXAND condition (2.16 vs 1.94,  $P=0.005$ ). (Table 3 and Fig. 2). Full-scale IQ was not significantly correlated with either expansion, *FMRI* mRNA or number of CGG repeats.

Analysis was also done to look at the presence of clinical conditions by other molecular measures namely number of CGG repeat numbers, number of AGG anchors and the AR. CGG repeat length did not differ significantly with presence of any clinical condition. However, among those with  $>105$  CGG repeats, there was a greater proportion of participants with ADHD compared to those with  $<105$  CGG repeats; although this was not statistically significant. The proportion of participants with ADHD was also highest in those with an AR between 0.21 and 0.40 as compared to other ranges. There were no other significant associations with CGG repeat numbers or AR for any clinical condition. Lastly, although in our analysis we observed differences in the number of AGG anchors, they did not reach significance with the presence of any clinical condition. As expected, after adjusting for AR, *FMRI* mRNA levels increased significantly with increasing number of CGG repeats ( $B=0.016$ ,  $SE=0.002$ ,  $P<0.001$ ) (Fig. 3). Further, the increase in levels of *FMRI* mRNA was clearly modulated by the AR, with participants who had a higher ratio having lower increase in *FMRI* mRNA levels.

Looking at demographic variables associated with clinical conditions, participants who had ADHD were significantly younger than those without the condition, as expected (mean age 47.0 years vs 52.0;  $P=0.037$ ). Those who had anxiety were much more likely to have a lower educational status as compared to those who did



**Figure 1.** Example of a PCR profile (visualized by a Capillary Electrophoretogram) observed in a female PM showing somatic allelic instability. The degree of CGG instability is shown as a shoulder pattern (serial of peaks) located to the right side of the premutation allele peak. Instability is calculated as Peak 2 (unstable premutation allele size, highest peak size of the shoulder pattern) minus Peak 1 (stable premutation allele size on the left of the shoulder pattern) as described in Hwang et al. 2022.

not have anxiety (47.0% with college education or higher vs 75.0%,  $P=0.034$ ). Age, educational attainment, or history of smoking were not associated with any other clinical condition.

Among the FXPOI sub-group, there was no significant association noted between presence of FXPOI and degree of expansion (median expansion in those with FXPOI vs those without FXPOI 2.0 vs 2.0,  $P=0.875$ ). The rate of FXPOI was associated with number of CGG repeats as shown in the bar plots in Fig. 4) with the highest prevalence observed in those carrying an allele in the mid-premutation range as previously reported<sup>30</sup>. Furthermore, CGG repeat length was significantly larger (median 3.0 vs 2.0,  $P=0.020$ ) and allelic expansion higher in subjects with ADHD (median 92.5 vs 87.0,  $P=0.027$ ). In the FXTAS sub-group, expansion was not associated with the presence or the stage of FXTAS. Interestingly, degree of expansion was lower in subjects with at least 1 diagnosis on the SCID-5 (0.0 vs 2.5,  $P=0.0428$ ), although this was based on a small number of subjects ( $N=18$ ).

## Discussion

This study sought to assess the clinical implications, if any, of somatic allelic expansion in a large cohort of female PM participants. Our main findings suggest that expansion is associated with significantly higher occurrence of ADHD among female PM. Further, higher levels of *FMR1* mRNA are associated with an occurrence of neuropsychiatric conditions including depression and ADHD. Lastly, levels of *FMR1* mRNA were significantly predicted by number of CGG repeats and by AR amongst female PM, confirming findings from previous studies<sup>31–33</sup>.

Our findings with respect to *FMR1* mRNA levels likely reflect the toxicity of elevated levels of mRNA, which has been shown to interfere with mitochondrial function, calcium regulation and cellular repair mechanisms as well as contributing to gain of function mutations<sup>13,15–17</sup>. These disruptions at the molecular level are thought to contribute to the increased pathology seen in PM, resulting in white matter disease in those with FXTAS and other psychiatric problems associated with FXAND. The positive association between *FMR1* mRNA levels and number of CGG repeats is not surprising and is consistent with previous literature<sup>13</sup>. Elevated levels of *FMR1* mRNA have also been shown to be associated with increased levels of psychological symptoms previously<sup>31,34</sup>; our findings add to this in terms of specific psychiatric conditions associated with mRNA levels. We further demonstrate here the crucial role played by the AR as the more favorable the ratio, with greater proportion of the non-mutated allele being active, the lower the excess mRNA produced.

It has also been shown that PM carriers who have higher repeat numbers (> 120 CGG) tend to have lower FMRP levels as well, likely due to the inefficiency of the translational process<sup>35,36</sup>. This combination of elevated mRNA levels and lowered FMRP levels could create a 'double-hit' phenomenon resulting in greater occurrence of disorders associated with both the reduced FMRP expression because translation inefficiency and RNA toxicity

	All Subjects (n = 424)			FXPOI ≥ 25 years (n = 377)			FXTAS, ≥ 50 years (n = 134)		
<b>Molecular Measures</b>	<b>n</b>	<b>Mean (SD)</b>	<b>Median (Range)</b>	<b>n</b>	<b>Mean (SD)</b>	<b>Median (Range)</b>	<b>n</b>	<b>Mean (SD)</b>	<b>Median (Range)</b>
Age	422	42.5 (17.2)	41 (0.3–90)	375	46.2 (14.2)	42 (25–90)	132	62.6 (9.4)	61 (50–90)
CGG	423	91.8 (22)	89 (55–196)	376	91.7 (20)	89.5 (55–190)	134	88 (19.3)	87 (55–161)
FMR1 mRNA	400	2.2 (0.9)	2.1 (0–7)	359	2.2 (0.9)	2.1 (0–7)	124	1.9 (0.9)	2 (0–7)
Instability	410	3.3 (6.1)	2 (0–56)	366	3.2 (5.9)	2 (0–56)	127	3.4 (5.9)	2 (0–56)
AGG	424	0.8 (0.8)	1 (0–2)	377	0.8 (0.8)	1 (0–2)	134	0.8 (0.8)	1 (0–2)
0		195 (46%)			172 (45.6%)			62 (46.3%)	
1		138 (32.5%)			125 (33.2%)			42 (31.3%)	
2		91 (21.5%)			80 (21.2%)			30 (22.4%)	
	All Subjects (n = 424)			FXPOI, ≥ 25 years (n = 377)			FXTAS, ≥ 50 years (n = 134)		
<b>Clinical Measures</b>	<b>n</b>	<b>No</b>	<b>Yes</b>	<b>n</b>	<b>No</b>	<b>Yes</b>	<b>n</b>	<b>No</b>	<b>Yes</b>
Medical conditions	187	62 (33.2%)	125 (66.8%)	180	58 (32.2%)	122 (67.8%)	93	20 (21.5%)	73 (78.5%)
Autoimmune conditions	187	145 (77.5%)	42 (22.5%)	180	138 (76.7%)	42 (23.3%)	93	66 (71%)	27 (29%)
SCID diagnosis	97	22 (22.7%)	75 (77.3%)	81	20 (24.7%)	61 (75.3%)	18	4 (22.2%)	14 (77.8%)
Autism	174	170 (97.7%)	4 (2.3%)	–	–	–	–	–	–
ADHD	187	138 (73.8%)	49 (26.2%)	180	133 (73.9%)	47 (26.1%)	93	73 (78.5%)	20 (21.5%)
Anxiety	181	41 (22.7%)	140 (77.3%)	175	40 (22.9%)	135 (77.1%)	91	23 (25.3%)	68 (74.7%)
Depression	184	67 (36.4%)	117 (63.6%)	177	64 (36.2%)	113 (63.8%)	90	29 (32.2%)	61 (67.8%)
Osteoporosis	141	122 (86.5%)	19 (13.5%)	134	115 (85.8%)	19 (14.2%)	76	58 (76.3%)	18 (23.7%)
FXAND	188	30 (16%)	158 (84%)	181	30 (16.6%)	151 (83.4%)	93	17 (18.3%)	76 (81.7%)
FXTAS Diagnosis	–	–	–	–	–	–	77	26 (33.8%)	51 (66.2%)
FXPOI	–	–	–	132	89 (67.4%)	43 (32.6%)	77	49 (63.6%)	28 (36.4%)
	<b>n</b>	<b>Mean (SD)</b>	<b>Median (Range)</b>	<b>n</b>	<b>Mean (SD)</b>	<b>Median (Range)</b>	<b>n</b>	<b>Mean (SD)</b>	<b>Median (Range)</b>
Full Scale IQ	122	119.8 (19)	118 (71–161)	122	119.8 (19)	118 (71–161)	70	116.3 (18.8)	112.5 (71–157)
Verbal IQ	123	97.2 (20.9)	103 (48–134)	123	97.2 (20.9)	103 (48–134)	70	94.3 (22.5)	102 (48–134)
Performance IQ	123	96.4 (27.1)	104 (31–150)	123	96.4 (27.1)	104 (31–150)	70	87.6 (26.3)	94 (31–138)
Total Subjects (n = 92)									
Smoking	n	Percentage		–	–	–	–	–	–
Current Smoker	5	5 (5.4%)	–	–	–	–	–	–	–
Former Smoker	30	30 (32.6%)	–	–	–	–	–	–	–
Never Smoker	57	57 (62%)	–	–	–	–	–	–	–
Total Subjects (n = 111)									
Education	n	Percentage							
Less Than High School	4	3.60%	–	–	–	–	–	–	–
High School/ GED	21	18.90%	–	–	–	–	–	–	–
Partial College	27	24.30%	–	–	–	–	–	–	–
College or Higher	59	53.20%	–	–	–	–	–	–	–

**Table 1.** Molecular and clinical data of participants included in the study.

due to the presence of elevated levels of *FMR1* mRNA<sup>37</sup>. Indeed, a series of cases including PM with CGG repeats in the upper premutation range has previously demonstrated a high occurrence of affective mood disorders, anxiety and psychotic thinking<sup>37</sup>. The combined pathology resultant of both increased mRNA and lowered FMRP is thought to contribute to this occurrence.

ADHD is a common neurodevelopmental disorder that seen in children and adolescents with a population prevalence rate of typically around 5.0% to 9.8%<sup>38–40</sup>. Elevated levels of ADHD have been demonstrated in PM in several studies<sup>10,12,41,42</sup>. Consistent with these reports, in our cohort of 424 participants, we observed that 26.2% of carriers had a diagnosis of ADHD; and this was more likely in younger participants in keeping with ADHD traditionally being considered a predominantly childhood neurodevelopmental disorder and limited awareness

	Median (25%, 75%) without conditions	Median (25%, 75%) with conditions	P-value
<i>Expansion by clinical conditions</i>			
FXAND	2 (0, 4)	2 (0, 5)	0.612
Medical conditions	2 (0, 4)	2 (0, 5)	0.703
Autoimmune conditions	2 (0, 4.25)	1 (0, 5)	0.207
SCID diagnosis	2 (0, 7)	2 (0, 4)	0.246
Autism	2 (0, 4.5)	2 (1, 2.5)	0.718
Anxiety	3 (0, 5)	2 (0, 4)	0.228
ADHD	2 (0, 3.5)	2.5 (0.25, 6)	<b>0.026</b>
Depression	2 (0, 4)	2 (0, 5)	0.497
Osteoporosis	2 (0, 4)	0 (0, 6)	0.671

**Table 2.** Expansion by clinical conditions. <sup>a</sup>P-values are from Wilcoxon rank-sum tests; FXAND: Fragile X-associated neurodevelopmental disorders, SCID: Structured Clinical Interview for DSM-5, ADHD: attention deficit hyperactivity disorder.


	Median (25%, 75%) without conditions	Median (25%, 75%) with conditions	P-value
<i>FMRI mRNA by clinical conditions</i>			
FXAND	1.94 (1.72, 2)	2.16 (1.87, 2.61)	<b>0.0045</b>
Medical conditions	2.3 (1.92, 2.68)	2.06 (1.75, 2.48)	0.066
Autoimmune conditions	2.095 (1.81, 2.58)	2.14 (1.89, 2.47)	0.782
SCID diagnosis	0.87 (0.78, 1.96)	1.98 (1.81, 2.47)	<b>0.0017</b>
Autism	2.1 (1.84, 2.56)	2.065 (1.90, 2.92)	0.859
Anxiety	1.96 (1.74, 2.60)	2.155 (1.88, 2.56)	0.395
ADHD	2.035 (1.72, 2.47)	2.295 (1.99, 2.7)	<b>0.0085</b>
Depression	1.975 (1.72, 2.37)	2.19 (1.89, 2.67)	<b>0.024</b>
Osteoporosis	2.06 (1.84, 2.47)	1.95 (1.53, 2.41)	0.65

**Table 3.** FMRI mRNA by clinical conditions. <sup>a</sup>P-values are from Wilcoxon rank-sum tests; FXAND: Fragile X associated neurodevelopmental disorders, SCID: Structured Clinical Interview for DSM-5, ADHD: attention deficit hyperactivity disorder.


and diagnosis of ADHD in adults in the past. Although the exact reasons for elevated rates of ADHD in PM are not yet clear, neuro-imaging of PM has demonstrated changes in grey matter voxel density in the amygdala, insula and caudate and this may be related to executive function challenges<sup>43</sup>. Furthermore, the increased vulnerability of PM neurons related to mRNA toxicity as discussed above is possibly related to attentional and emotional regulation difficulties<sup>15</sup>. The presence of expansion could be a further modulator of this effect within the nervous system. Importantly, given what is seen in a mouse model of the FXDs<sup>44</sup>, and in patients with other repeat expansion diseases<sup>45,46</sup>, the degree of expansion may be higher in the brain compared to peripheral blood from which this study's samples were obtained. As we previously showed, given that expansion increases with the number of CGG repeats and that the latter correlates with *FMRI* mRNA levels, the presence of expansion could be a marker for elevated mRNA related toxicity. This may explain the greater occurrence of ADHD within our cohort. However, one of the limitations of our study is that our data was restricted in terms of subtypes of severity and ADHD (inattentive vs hyperactive-impulsive). Thus, future research into the implications of expansion on the nature of ADHD is warranted to shed light on possible associative mechanisms. Further, this study includes a small sample size especially for some of the clinical conditions investigated at various age points, which was related to data availability in medical record review. Consequently, the study may have had limited statistical power for detection of significant associations. Increasing the overall sample size and targeted recruitment of PM of specific age groups could help overcome this in future studies. In addition, participants included were not a population sample but rather a mixture of PM seen for clinical concerns and identified by cascade testing. Hence prevalence of clinical conditions such as FXAND conditions could be higher than true prevalence values. However, this preliminary data suggest a potential role of allelic somatic expansion as a biomarker that may be useful for assessing prognosis and clinical management of patients PM.

## Conclusion

Somatic *FMRI* allele expansion was associated with the presence of ADHD in female PM. In addition, higher *FMRI* mRNA levels were associated with the presence of multiple neuropsychiatric conditions as well as increased number of CGG repeats. As such, this work is of relevance as it indicates that somatic allelic CGG expansion could be a potential molecular marker for the manifestation of neuropsychiatric conditions in PM. It is, therefore, original, as it constitutes the first study where somatic instability of the *FMRI* CGG repeat has been




**Figure 2.** Significant association between *FMR1* mRNA levels and the presence of clinical conditions.



**Figure 3.** Scatterplot of correlation between *FMR1* mRNA levels by CGG repeat number, stratified by activation ratio.





**Figure 4.** Association between rate of FXPOI and CGG repeat number.

associated with clinical conditions in a large cohort of female PM. Further research on the clinical implications of expansion could potentially help to discern the clinical phenotype and guide prognostication and management of these conditions in these individuals.

### Data availability

Data can be made available on reasonable request to the corresponding author.

Received: 10 November 2022; Accepted: 14 April 2023

Published online: 29 April 2023

### References

- Hagerman, R. J. H., P. J., *Fragile X Syndrome and Premutation Disorders*. 2020, Mac Keith Press.
- Tassone, F. *et al.* FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. *Genome Med.* **4**(12), 100 (2012).
- Jacquemont, S. *et al.* Fragile X premutation tremor/ataxia syndrome: Molecular, clinical, and neuroimaging correlates. *Am. J. Hum. Genet.* **72**(4), 869–878 (2003).
- Sullivan, A. K. *et al.* Association of FMR1 repeat size with ovarian dysfunction. *Hum. Reprod.* **20**(2), 402–412 (2005).
- Hagerman, R. J. *et al.* Fragile X-associated neuropsychiatric disorders (FXAND). *Front. Psychiatry* **9**, 564 (2018).
- Hagerman, R. J. & Hagerman, P. Fragile X-associated tremor/ataxia syndrome—features, mechanisms and management. *Nat. Rev. Neurol.* **12**(7), 403–412 (2016).
- Hagerman, R. & Hagerman, P. Fragile X-associated tremor/ataxia syndrome: Pathophysiology and management. *Curr. Opin. Neurol.* **34**(4), 541–546 (2021).
- Cordeiro, L. *et al.* Anxiety disorders in fragile X premutation carriers: Preliminary characterization of probands and non-probands. *Intractable Rare Dis. Res.* **4**(3), 123–130 (2015).
- Bourgeois, J. A. *et al.* Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. *Gen. Hosp. Psychiatry* **29**(4), 349–356 (2007).
- Farzin, F. *et al.* Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. *J. Dev. Behav. Pediatr.* **27**(2 Suppl), S137–S144 (2006).
- Clifford, S. *et al.* Autism spectrum phenotype in males and females with fragile X full mutation and premutation. *J. Autism. Dev. Disord.* **37**(4), 738–747 (2007).
- Bailey, D. B. Jr. *et al.* Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. *Am. J. Med. Genet. A* **146A**(16), 2060–2069 (2008).
- Tassone, F. *et al.* Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the fragile-X syndrome. *Am. J. Hum. Genet.* **66**(1), 6–15 (2000).
- Galloway, J. N. & Nelson, D. L. Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome. *Fut. Neurol.* **4**(6), 785–798 (2009).
- Chen, Y. *et al.* Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. *Hum. Mol. Genet.* **19**(1), 196–208 (2010).
- Robin, G. *et al.* Calcium dysregulation and Cdk5-ATM pathway involved in a mouse model of fragile X-associated tremor/ataxia syndrome. *Hum. Mol. Genet.* **26**(14), 2649–2666 (2017).
- Napoli, E. *et al.* Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. *Hum. Mol. Genet.* **20**(15), 3079–3092 (2011).
- Hwang, Y. H. *et al.* Both cis and trans-acting genetic factors drive somatic instability in female carriers of the FMR1 premutation. *Sci. Rep.* **12**(1), 10419 (2022).
- Lord, C., *et al.*, *Autism Diagnostic Observation Schedule Second Edition (ADOS-2) Manual (Part 1): Modules 1–4*. Torrance, CA: Western Psychological Services, 2012.
- First, M. B., *Structured clinical interview for the DSM (SCID)*. The encyclopedia of clinical psychology, 2014: p. 1–6.
- Kaufman, J. *et al.* Schedule for affective disorders and schizophrenia for school-age children—present and lifetime version (K-SADS-PL): Initial reliability and validity data. *J. Am. Acad. Child Adolesc. Psychiatry* **36**(7), 980–988 (1997).
- Wechsler, D., *Wechsler abbreviated scale of intelligence*. 1999: Psychological Corporation.

23. Roid, G.H. and M. Pomplun, *The Stanford-Binet Intelligence Scales*. 2012: The Guilford Press.
24. Wechsler, D., *Wechsler adult Intelligence Scale*. Archives of Clinical Neuropsychology, 1955.
25. Tassone, F. *et al.* A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. *J. Mol. Diagn.* **10**(1), 43–49 (2008).
26. Filipovic-Sadic, S. *et al.* A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. *Clin. Chem.* **56**(3), 399–408 (2010).
27. Tassone, F. *et al.* FMRP expression as a potential prognostic indicator in fragile X syndrome. *Am. J. Med. Genet.* **84**(3), 250–261 (1999).
28. Yrigollen, C. M. *et al.* AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. *Genet. Med.* **14**(8), 729–736 (2012).
29. Villate, O. *et al.* Effect of AGG interruptions on FMR1 maternal transmissions. *Front. Mol. Biosci.* **7**, 135 (2020).
30. Allen, E. G. *et al.* Refining the risk for fragile X-associated primary ovarian insufficiency (FXPOI) by FMR1 CGG repeat size. *Genet. Med.* **23**(9), 1648–1655 (2021).
31. Johnson, D., *et al.*, Increased pain symptomatology among females vs. males with fragile X-associated tremor/ataxia syndrome. *Front. Psychiatry*, 2021. **12**.
32. Tassone, F. *et al.* Transcription of the FMR1 gene in individuals with fragile X syndrome. *Am. J. Med. Genet.* **97**(3), 195–203 (2000).
33. Yrigollen, C. M. *et al.* The role of AGG interruptions in the transcription of FMR1 premutation alleles. *PLoS ONE* **6**(7), e21728 (2011).
34. Hessel, D. *et al.* Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **139**(1), 115–121 (2005).
35. Ludwig, A. L. *et al.* CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size. *Hum. Mol. Genet.* **23**(12), 3228–3238 (2014).
36. Pretto, D. I. *et al.* Differential increases of specific FMR1 mRNA isoforms in premutation carriers. *J. Med. Genet.* **52**(1), 42–52 (2015).
37. Schneider, A. *et al.* Elevated FMR1-mRNA and lowered FMRP—a double-hit mechanism for psychiatric features in men with FMR1 premutations. *Transl. Psychiatry* **10**(1), 1–8 (2020).
38. Ghandour, R. M. *et al.* Prevalence and treatment of depression, anxiety, and conduct problems in US children. *J. Pediatr.* **206**, 256–267.e3 (2019).
39. Bitsko, R. H. *et al.* Mental health surveillance among children—United States, 2013–2019. *MMWR Suppl.* **71**(2), 1–42 (2022).
40. Sayal, K. *et al.* ADHD in children and young people: Prevalence, care pathways, and service provision. *Lancet Psychiatry* **5**(2), 175–186 (2018).
41. Dorn, M. B., Mazzocco, M. M. & Hagerman, R. J. Behavioral and psychiatric disorders in adult male carriers of fragile X. *J. Am. Acad. Child Adolesc. Psychiatry* **33**(2), 256–264 (1994).
42. Hunter, J. E. *et al.* The FMR1 premutation and attention-deficit hyperactivity disorder (ADHD): Evidence for a complex inheritance. *Behav. Genet.* **42**(3), 415–422 (2012).
43. Moore, C. J. *et al.* The effect of pre-mutation of X chromosome CGG trinucleotide repeats on brain anatomy. *Brain* **127**(Pt 12), 2672–2681 (2004).
44. Zhao, X.-N. & Usdin, K. Timing of expansion of fragile X premutation alleles during intergenerational transmission in a mouse model of the fragile X-related disorders. *Front. Genet.* **9**, 314 (2018).
45. Kacher, R. *et al.* Propensity for somatic expansion increases over the course of life in Huntington disease. *Elife* **10**, e64674 (2021).
46. Campion, L. N. *et al.* Tissue-specific and repeat length-dependent somatic instability of the X-linked dystonia parkinsonism-associated CCCTCT repeat. *Acta Neuropathol. Commun.* **10**(1), 1–16 (2022).

## Acknowledgements

We thank the families who have participated in our studies and also the Fragile X team including students at the MIND Institute for their excellent collaboration.

## Author contributions

R.A. conceptualized the article and wrote the first draft. Y.H. carried out the molecular measures described in the study and was a major contributor to the manuscript. E.S. was involved in clinical data measurements and contributed to versions of the manuscript. B.H. and K.U. carried out measures of instability. B.J. conducted all the statistical analysis involved and reported in the manuscript. R.H. contributed to study data collection and critically reviewed the manuscript. F.T. conceptualized the study, oversaw all the molecular measures involved, critically reviewed and revised versions of the manuscript. All authors read, reviewed and approved the final manuscript.

## Funding

This research was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number P50 HD103526 and HD036071. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Competing interests

The authors declare no competing interests.

## Additional information

**Correspondence** and requests for materials should be addressed to F.T.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023